Cystic Fibrosis Treatment Market: Global Share, Size, Growth, Trends & Outlook ( 2022 – 2032 )

Cystic Fibrosis Treatment Market Insights

The global Cystic Fibrosis Treatment Market size was valued at around $15.1 billion in 2021 and is projected to grow at a compound annual rate of growth (CAGR) of around 15.2% from 2022 to 2032.The market size is projected to succeed in $48.2 billion by 2032.

Cystic Fibrosis Understanding and Treatment Algorithm

Cystic Fibrosis (CF) is a genetic disease that affects the respiratory, digestive, and reproductive systems. It's caused by mutations within the CF transmembrane conductance regulator (CFTR) gene, which produces a protein that regulates the movement of salt and water in and out of cells. These mutations cause the assembly of a defective CFTR protein, which ends up in thick, sticky mucus buildup within the lungs, pancreas, and other organs.

Symptoms of CF can vary widely, but typically include chronic lung infections, coughing, wheezing, shortness of breath, poor growth and weight gain despite adequate nutrition, salty-tasting skin, and frequent bowel movements or constipation. The severity of CF can vary widely, with some people experiencing only mild symptoms while others may have more severe diseases. Cystic fibrosis is a rare disease, affecting about 30,000 people within the USA and 70,000 people worldwide. The life expectancy for people with CF has improved significantly in recent years, due partially to advances in treatment.

Treatments available for Cystic Fibrosis

Treatment for CF is aimed at managing the symptoms and preventing complications. The treatment plan is usually individualized and supported the precise symptoms and severity of the disease. Here are a number of the common treatments for CF:

• Medications: Several medications are used to treat CF, including antibiotics to treat lung infections, anti-inflammatory drugs to scale back lung inflammation, and bronchodilators to assist open up airways.
• Airway Clearance Techniques: Airway clearance techniques, like chest physiotherapy, high-frequency chest wall oscillation, and positive expiratory pressure therapy, help to loosen and take away mucus from the lungs, making it easier to breathe.
• Nutritional Support: People with CF often have difficulty absorbing nutrients from food, so nutritional support is a crucial part of treatment. this might involve taking enzyme supplements to assist digest food, also as eating a high-calorie, high-fat diet.
• Exercise: Regular exercise can help to enhance lung function and overall health in people with CF. Exercise also helps to loosen mucus and make it easier to cough up.
• Lung Transplant: In severe cases of CF where lung function has deteriorated significantly, a lung transplant could also be necessary.
• Gene Therapy: Gene therapy is an emerging treatment for CF that involves delivering healthy copies of the CFTR gene to the lungs. While this treatment remains within the experimental stages, it's shown promising leads to clinical trials.

Cystic Fibrosis treatment emerging drugs

There are several emerging drugs for the treatment of CF that are in various stages of development. These include:

• Elexacaftor/tezacaftor/ivacaftor (Trikafta): This combination therapy was approved by the U.S. Food and Drug Administration (FDA) in 2019 and is currently the foremost effective treatment available for people with CF. It's a mixture of three drugs that helps to correct the abnormal function of the CFTR protein.
• VX-659/tezacaftor/ivacaftor (Trikafta-E): This combination therapy is being developed by Vertex Pharmaceuticals and is currently in phase 3 clinical trials. It’s almost like Trikafta but includes a further drug, VX-659, which is meant to assist correct a wider range of CFTR mutations.
• VX-561: This drug, developed by Vertex Pharmaceuticals, is meant to assist correct the abnormal function of the CFTR protein. it's currently in phase 2 clinical trials.
• VX-445/tezacaftor/ivacaftor (Symdeko): This mix therapy was approved by the FDA in 2018 and is additionally available for the treatment of CF. It's a mixture of three drugs that helps to correct the abnormal function of the CFTR protein.
• AZD1940: This drug, developed by AstraZeneca, is meant to assist correct the abnormal function of the CFTR protein, currently in phase 2 clinical trials.
• RG-7916: This drug, developed by Roche, is meant to assist correct the abnormal function of the CFTR protein, currently in phase 2 clinical trials.

Cystic Fibrosis Treatment Market

In 2020, the worldwide CF market was valued at $5.04 billion, and it's expected to succeed at $10.77 billion by 2025, at a compound annual rate of growth (CAGR) of 13.5% from 2021 to 2025. The rise in market size is essentially thanks to the increasing prevalence of CF and therefore the development of the latest treatments. This growth is driven by several factors, including an increased prevalence of CF, advances in treatment options, and rising investments in research and development. The market is dominated by several key players, including Vertex Pharmaceuticals, AbbVie Inc., Novartis AG, and Gilead Sciences, among others. These companies are investing heavily in the development of the latest therapies and coverings for CF, which is predicted to contribute to the expansion of the market within the coming years.

Cystic Fibrosis Treatment Market Driving Factors:

Several factors are driving the growth of the CF treatment market:

• Development of new treatments: There has been a big rise in the development of the latest treatments for CF in recent years, with several new drugs being developed and approved by regulatory agencies contributing to the expansion of the CF market.
• Government initiatives: Many governments around the world are providing funding and support for the research and development of CF treatments. For instance, the US government provides funding for the CF Foundation, which supports research and development of the latest treatments.  These initiatives have helped to extend the supply and affordability of different CF therapies, contributing to the expansion of the market.
• Improved life expectancy: Advances in treatment have led to an improvement in the life expectancy of individuals with CF increasing the number of individuals with the disease who live longer and need ongoing treatment, which has contributed to the expansion of the market.
• Increasing awareness and diagnosis: Increased awareness of CF has led to earlier diagnosis and treatment, which is predicted to drive demand for CF treatments.
• Increasing prevalence of CF: CF is a genetic disorder that affects approximately 70,000 people worldwide. The increasing prevalence of the disease is expected to drive the demand for effective treatments.
• Rising healthcare expenditure: Healthcare expenditure has been increasing globally, which has led to a rise in the demand for and availability of treatments for various diseases, including CF.
• Rising investments in research and development: Pharmaceutical companies are investing heavily in the development of the latest treatments for CF. For instance, Vertex Pharmaceuticals has invested over $12 billion in research and development for CF treatments.
• Technological advancements: Advances in technology have led to the event of the latest treatments and therapies for CF. For instance, Vertex Pharmaceuticals' CFTR modulators have shown promising leads to clinical trials and are now getting used to treat patients with certain genetic mutations that cause CF.

Cystic Fibrosis Treatment Market Segmentation

The global CF market can be segmented as follows:

• By treatment type: CFTR Modulators, Mucolytics, Pancreatic Enzyme Supplements, Antibiotics, Bronchodilators
• By route of administration: Oral, Inhaled, Intravenous
• By end-user type: Hospitals, Clinics, Home Care Settings
• By geography: North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Cystic Fibrosis Treatment Market Regional Synopsis

The US and Canada are the largest markets for Cystic Fibrosis treatment in North America, with a market share of approximately 60%. The high prevalence of disease in these countries, along with favorable government initiatives, drives the growth of the market in this region. The North American market size is expected to reach $8.9 billion by 2025, with a CAGR of 14.1% (2021-2025). The European CF treatment market is driven by increasing government funding for research and development of new treatments, along with a rising prevalence of the disease with the UK, Germany, and France being some of the major markets. The market is expected to grow at a CAGR of 15.2% during the forecast period (2021-2025) to reach $5.2 billion by 2025.

The Asia Pacific Cystic Fibrosis treatment market is expected to grow at a significant rate due to an increasing prevalence of the disease in countries like India and China. It is expected to grow at a CAGR of 16.6% (2021-2025), to reach $2.7 billion by 2025 due to reasons such as growing healthcare infrastructure and increasing investments in research and development activities. The Latin American CF treatment market is driven by increasing government initiatives and rising awareness about the disease. Brazil and Mexico as major markets and the market is expected to grow at a CAGR of 16.1% to reach $790 million by 2025.

The Cystic Fibrosis treatment market in the Middle East & Africa is driven by increasing investments in the healthcare sector and rising awareness about the disease. South Africa and Saudi Arabia are some of the major markets in this region. The treatment market is expected to grow at a CAGR of 14.5% during the forecast period. The market size is projected to reach $570 million by 2025 with the key drivers including increasing investments in healthcare infrastructure, rising awareness about the disease, and favorable government initiatives.

Cystic Fibrosis Treatment Market Development in Japan

The Cystic Fibrosis treatment market in Japan remains in its early stages and is comparatively small compared to other developed countries and was estimated to be around $12 million in 2020. The treatment market is predicted to grow at a CAGR of around 10% during the forecast period of 2021-2025. There are several recent industry developments in Japan associated with the treatment of CF:

• In 2019, Vertex Pharmaceuticals received marketing approval from the Japanese Ministry of Health, Labour, and Welfare for the utilization of its drug Symdeko (a combination of VX-445 and tezacaftor/ivacaftor) within the treatment of CF.
• In 2020, the Japanese Ministry of Health, Labour, and Welfare approved the utilization of Trikafta (a combination of elexacaftor/tezacaftor/ivacaftor) in the treatment of CF. This drug was developed by Vertex Pharmaceuticals and is currently the foremost effective treatment available for people with CF.
• In 2021, AstraZeneca announced that it had received approval from the Japanese Ministry of Health, Labour, and Welfare for the utilization of its drug Pulmozyme within the treatment of CF. Pulmozyme may be a mucolytic agent that helps to interrupt and take away mucus from the airways.
• There also are several other emerging drugs for the treatment of CF in development in Japan, including AZD1940, developed by AstraZeneca, and RG-7916, developed by Roche which are currently in clinical trials and aren't yet available on the market.

Cystic Fibrosis Treatment Market Challenges

There are several challenges facing the cystic fibrosis market:

• Disease complexity and late diagnosis: CF is a complex disease with many various symptoms and complications, which may make it difficult to manage effectively. Also, it is usually diagnosed late, which may delay the beginning of treatment and cause poorer outcomes for patients.
• High cost of treatment: The value of treating CF is often high because it often requires a mixture of medicines, nutrition therapy, and respiratory therapy. This will be a financial burden for patients and their families, especially in developing countries.
• Increasing competition: With the approval of multiple CFTR modulators, the CF treatment market is becoming increasingly competitive creating challenges for pharmaceutical companies seeking to bring new treatments to plug.
• Lack of awareness: CF is a rare disease, and lots of healthcare professionals and members of the overall public have limited awareness and understanding of the disease, which may cause delays in diagnosis and treatment.
• Lack of cures: While there are several treatments available for CF, there's currently no cure for the disease. This suggests that folks with CF must undergo ongoing treatment for the remainder of their lives.
• Limited patient population: CF affects about 30,000 people within the USA and 70,000 people worldwide. This small patient population can limit the financial viability of developing and marketing treatments for the disease.
• Limited treatment options: While there are some recent advancements within the development of CF treatments, the amount of treatment options remain limited, particularly for patients with rare mutations.
• Patent expirations: Several of the main CF treatments are nearing the top of their patent exclusivity, which can cause increased competition and lower prices.
• Patient adherence: CF treatments often require strict adherence to a treatment regimen, including daily medications, breathing treatments, and physiotherapy. this will be challenging for a few patients, particularly children, and teenagers.
• Regulatory challenges: Developing new drugs for the treatment of CF is often a posh and time-consuming process, as these drugs must undergo a variety of clinical trials and regulatory hurdles before they will be approved to be used posing a challenge for companies developing new treatments for the disease.

Cystic Fibrosis Treatment Market Key Players

There are several key players in the cystic fibrosis market:

• AbbVie Inc.: AbbVie is a drug company that markets the drug, Creon, which is employed to enhance digestion in patients with pancreatic insufficiency thanks to CF.
• AstraZeneca: AstraZeneca, is a global drug company that markets the drug Pulmozyme for the treatment of CF. it's also developing several other drugs for the treatment of CF, including AZD1940 and AZD9150.
• Chiesi Farmaceutici: Chiesi Farmaceutici markets Bronchitol, a dry powder inhalation wont to improve lung function in CF patients.
• F. Hoffmann-La Roche Ltd.: Roche markets Pulmozyme in certain countries, and is additionally involved in the development of the latest CF treatments.
• Genentech: Genentech markets Pulmozyme, an inhaled enzyme used to improves lung function and reduces the frequency of respiratory infections in CF patients.
• Gilead Sciences: Gilead Sciences is a global drug company that markets the drug Cayston for the treatment of CF. Cayston is an inhaled antibiotic that's wont to treat respiratory infections in people with CF.
• Novartis: A global drug company that markets the drug TOBI Podhaler for the treatment of CF. TOBI Podhaler may be a nebulized sort of antibiotic tobramycin, which is employed to treat respiratory infections in people with CF.
• Pfizer Inc.: Pfizer markets Tobi Podhaler, an inhaled antibiotic wont to treat lung infections in CF patients.
• Roche: Roche is a global drug company that markets the drug Pulmozyme for the treatment of CF. Pulmozyme may be a mucolytic agent that helps to interrupt and take away mucus from the airways.
• Vertex Pharmaceuticals: Vertex Pharmaceuticals may be a biopharmaceutical company that focuses on the event of medicine for CF. Their CFTR modulator drugs, including Kalydeco, Orkambi, Symdeko, and Trikafta, have revolutionized the treatment of CF.